Sophie Lanzkron

List of Publications by Year
in descending order

158 papers	7,674 citations	53794 45 h-index	54911 84 g-index
160 all docs	160 docs citations	160 times ranked	5921 citing authors

#	Article	IF	Citations
1	Management of Sickle Cell Disease. JAMA - Journal of the American Medical Association, 2014, 312, 1033.	7.4	1,189
2	A Phase 3 Trial of<scp>l</scp>-Glutamine in Sickle Cell Disease. New England Journal of Medicine, 2018, 379, 226-235.	27.0	378
3	Mortality Rates and Age at Death from Sickle Cell Disease: U.S., 1979â€“2005. Public Health Reports, 2013, 128, 110-116.	2.5	354
4	Systematic Review: Hydroxyurea for the Treatment of Adults with Sickle Cell Disease. Annals of Internal Medicine, 2008, 148, 939.	3.9	224
5	Do Words Matter? Stigmatizing Language and the Transmission of Bias in the Medical Record. Journal of General Internal Medicine, 2018, 33, 685-691.	2.6	217
6	Hospitalization for pain in patients with sickle cell disease treated with sildenafil for elevated TRV and low exercise capacity. Blood, 2011, 118, 855-864.	1.4	210
7	Nitric Oxide for Inhalation in the Acute Treatment of Sickle Cell Pain Crisis. JAMA - Journal of the American Medical Association, 2011, 305, 893.	7.4	196
8	Hydroxyurea for Sickle Cell Disease: A Systematic Review for Efficacy and Toxicity in Children. Pediatrics, 2008, 122, 1332-1342.	2.1	189
9	Randomized phase 2 study of GMI-1070 in SCD: reduction in time to resolution of vaso-occlusive events and decreased opioid use. Blood, 2015, 125, 2656-2664.	1.4	178
10	The burden of emergency department use for sickleâ€cell disease: An analysis of the national emergency department sample database. American Journal of Hematology, 2010, 85, 797-799.	4.1	176
11	The relationship between the severity of hemolysis, clinical manifestations and risk of death in 415 patients with sickle cell anemia in the US and Europe. Haematologica, 2013, 98, 464-472.	3.5	170
12	Association of Sickle Cell Trait With Chronic Kidney Disease and Albuminuria in African Americans. JAMA - Journal of the American Medical Association, 2014, 312, 2115.	7.4	167
13	Estimated Life Expectancy and Income of Patients With Sickle Cell Disease Compared With Those Without Sickle Cell Disease. JAMA Network Open, 2019, 2, e1915374.	5.9	163
14	Venous Thromboembolism in Adults with Sickle Cell Disease: A Serious and Under-recognized Complication. American Journal of Medicine, 2013, 126, 443-449.	1.5	156
15	Hospitalization rates and costs of care of patients with sickle-cell anemia in the state of Maryland in the era of hydroxyurea. American Journal of Hematology, 2006, 81, 927-932.	4.1	140
16	A Systematic Review of Barriers and Interventions to Improve Appropriate Use of Therapies for Sickle Cell Disease. Journal of the National Medical Association, 2009, 101, 1022-1033.	0.8	135
17	Echocardiographic Markers of Elevated Pulmonary Pressure and Left Ventricular Diastolic Dysfunction Are Associated With Exercise Intolerance in Adults and Adolescents With Homozygous Sickle Cell Anemia in the United States and United Kingdom. Circulation, 2011, 124, 1452-1460.	1.6	124
18	Venous thromboembolism incidence in the Cooperative Study of Sickle Cell Disease. Journal of Thrombosis and Haemostasis, 2014, 12, 2010-2016.	3.8	123

#	Article	IF	Citations
19	The course and correlates of high hospital utilization in sickle cell disease: Evidence from a large, urban Medicaid managed care organization. American Journal of Hematology, 2009, 84, 666-670.	4.1	112
20	Risk Factors for Death in 632 Patients with Sickle Cell Disease in the United States and United Kingdom. PLoS ONE, 2014, 9, e99489.	2.5	107
21	Comparison of US Federal and Foundation Funding of Research for Sickle Cell Disease and Cystic Fibrosis and Factors Associated With Research Productivity. JAMA Network Open, 2020, 3, e201737.	5.9	102
22	High prevalence and correlates of low bone mineral density in young adults with sickle cell disease. American Journal of Hematology, 2006, 81, 236-241.	4.1	100
23	Provider Barriers to Hydroxyurea Use in Adults with Sickle Cell Disease: A Survey of the Sickle Cell Disease Adult Provider Network. Journal of the National Medical Association, 2008, 100, 968-974.	0.8	99
24	The impact of race and disease on sickle cell patient wait times in the emergency department. American Journal of Emergency Medicine, 2013, 31, 651-656.	1.6	98
25	Perceived Discrimination, Patient Trust, and Adherence to Medical Recommendations Among Persons with Sickle Cell Disease. Journal of General Internal Medicine, 2014, 29, 1657-1662.	2.6	96
26	Perceived Discrimination in Health Care Is Associated With a Greater Burden of Pain in Sickle Cell Disease. Journal of Pain and Symptom Management, 2014, 48, 934-943.	1.2	91
27	American Society of Hematology 2019 guidelines for sickle cell disease: cardiopulmonary and kidney disease. Blood Advances, 2019, 3, 3867-3897.	5.2	87
28	Sickle cell disease and venous thromboembolism: what the anticoagulation expert needs to know. Journal of Thrombosis and Thrombolysis, 2013, 35, 352-358.	2.1	79
29	An Evaluation of Central Sensitization in Patients With Sickle Cell Disease. Journal of Pain, 2016, 17, 617-627.	1.4	79
30	The excess burden of stroke in hospitalized adults with sickle cell disease. American Journal of Hematology, 2009, 84, 548-552.	4.1	75
31	The Association of Provider Communication with Trust among Adults with Sickle Cell Disease. Journal of General Internal Medicine, 2010, 25, 543-548.	2.6	71
32	The epidemiology, evaluation and treatment of stroke in adults with sickle cell disease. Expert Review of Hematology, 2011, 4, 597-606.	2.2	70
33	A Video-Intervention to Improve Clinician Attitudes Toward Patients with Sickle Cell Disease: The Results of a Randomized Experiment. Journal of General Internal Medicine, 2011, 26, 518-523.	2.6	68
34	Chronic Opioid Therapy and Central Sensitization in Sickle Cell Disease. American Journal of Preventive Medicine, 2016, 51, S69-S77.	3.0	65
35	Vasculopathy, inflammation, and blood flow in leg ulcers of patients with sickle cell anemia. American Journal of Hematology, 2014, 89, 1-6.	4.1	62
36	Building access to care in adult sickle cell disease: defining models of care, essential components, and economic aspects. Blood Advances, 2020, 4, 3804-3813.	5.2	57

#	Article	IF	Citations
37	Ex-vivo expansion of bone marrow progenitor cells for hematopoietic reconstitution following high-dose chemotherapy for breast cancer. Experimental Hematology, 1999, 27, 615-623.	0.4	55
38	Health care provider attitudes toward patients with acute vaso-occlusive crisis due to sickle cell disease: Development of a scale. Patient Education and Counseling, 2009, 76, 272-278.	2.2	55
39	The Measure of Sickle Cell Stigma: Initial findings from the Improving Patient Outcomes through Respect and Trust study. Journal of Health Psychology, 2016, 21, 808-820.	2.3	53
40	Multiple Levels of Suffering. Clinical Journal of Pain, 2016, 32, 1076-1085.	1.9	52
41	Problematic Hospital Experiences among Adult Patients with Sickle Cell Disease. Journal of Health Care for the Poor and Underserved, 2010, 21, 1114-1123.	0.8	51
42	Examining the characteristics and beliefs of hydroxyurea users and nonusers among adults with sickle cell disease. American Journal of Hematology, 2011, 86, 85-87.	4.1	50
43	Prediction of onset and course of high hospital utilization in sickle cell disease. Journal of Hospital Medicine, 2011, 6, 248-255.	1.4	48
44	The association between sickle cell disease and dental caries in African Americans. Special Care in Dentistry, 2006, 26, 95-100.	0.8	47
45	Quantitative sensory testing and pain-evoked cytokine reactivity. Pain, 2016, 157, 949-956.	4.2	47
46	Hospital self-discharge among adults with sickle-cell disease (SCD): Associations with trust and interpersonal experiences with care. Journal of Hospital Medicine, 2010, 5, 289-294.	1.4	46
47	Provider Barriers to Hydroxyurea Use in Adults with Sickle Cell Disease: A Survey of the Sickle Cell Disease Adult Provider Network. Journal of the National Medical Association, 2008, 100, 968.	0.8	44
48	Provider barriers to hydroxyurea use in adults with sickle cell disease: a survey of the Sickle Cell Disease Adult Provider Network. Journal of the National Medical Association, 2008, 100, 968-73.	0.8	44
49	Impact of a dedicated infusion clinic for acute management of adults with sickle cell pain crisis. American Journal of Hematology, 2015, 90, 376-380.	4.1	43
50	Daily Opioid Use Fluctuates as a Function of Pain, Catastrophizing, and Affect in Patients With Sickle Cell Disease: An Electronic Daily Diary Analysis. Journal of Pain, 2018, 19, 46-56.	1.4	39
51	Sickle Cell Disease. Annals of Internal Medicine, 2021, 174, ITC1-ITC16.	3.9	38
52	An unequal burden: Poor patientâ€“provider communication and sickle cell disease. Patient Education and Counseling, 2014, 96, 159-164.	2.2	37
53	Evidence gaps in the management of sickle cell disease: A summary of needed research. American Journal of Hematology, 2015, 90, 273-275.	4.1	37
54	Polymerized human Hb use in acute chest syndrome: a case report. Transfusion, 2002, 42, 1422-1427.	1.6	36

#	Article	IF	Citations
55	A Preliminary Study of Psychiatric, Familial, and Medical Characteristics of High-utilizing Sickle Cell Disease Patients. Clinical Journal of Pain, 2013, 29, 317-323.	1.9	33
56	Religious coping and hospital admissions among adults with sickle cell disease. Journal of Behavioral Medicine, 2011, 34, 120-127.	2.1	31
57	Increased acute care utilization in a prospective cohort of adults with sickle cell disease. Blood Advances, 2018, 2, 2412-2417.	5.2	31
58	Disease-Related, Nondisease-Related, and Situational Catastrophizing in Sickle Cell Disease and Its Relationship With Pain. Journal of Pain, 2016, 17, 1227-1236.	1.4	29
59	Transition to adulthood and adult health care for patients with sickle cell disease or cystic fibrosis: Current practices and research priorities. Journal of Clinical and Translational Science, 2018, 2, 334-342.	0.6	28
60	Risks associated with fertility preservation for women with sickle cell anemia. Fertility and Sterility, 2018, 110, 720-731.	1.0	28
61	Primary Care Providersâ€™ Comfort Levels in Caring for Patients with Sickle Cell Disease. Southern Medical Journal, 2015, 108, 531-536.	0.7	28
62	Homing of Long-Term and Short-Term Engrafting Cells In Vivoa. Annals of the New York Academy of Sciences, 1999, 872, 48-56.	3.8	26
63	Baby on board: what you need to know about pregnancy in the hemoglobinopathies. Hematology American Society of Hematology Education Program, 2012, 2012, 208-214.	2.5	25
64	Improving Emergency Providersâ€™ Attitudes Toward Sickle Cell Patients in Pain. Journal of Pain and Symptom Management, 2016, 51, 628-632.e3.	1.2	25
65	National trends in hydroxyurea and opioid prescribing for sickle cell disease by officeâ€based physicians in the United States, 1997â€2017. Pharmacoepidemiology and Drug Safety, 2019, 28, 1246-1250.	1.9	25
66	Hydroxycarbamide exposure and ovarian reserve in women with sickle cell disease in the Multicenter Study of Hydroxycarbamide. British Journal of Haematology, 2020, 191, 880-887.	2.5	25
67	Examining the Effectiveness of Hydroxyurea in People with Sickle Cell Disease. Journal of Health Care for the Poor and Underserved, 2010, 21, 277-286.	0.8	24
68	Risk factors for venous thromboembolism in adults with hemoglobin SC or SÎ²+ thalassemia genotypes. Thrombosis Research, 2016, 141, 35-38.	1.7	22
69	A prospective quality improvement initiative in adult hemophagocytic lymphohistiocytosis to improve testing and a framework to facilitate trigger identification and mitigate hemorrhage from retrospective analysis. Medicine (United States), 2018, 97, e11579.	1.0	20
70	Clinical and Ophthalmic Factors Associated With the Severity of Sickle Cell Retinopathy. American Journal of Ophthalmology, 2019, 197, 105-113.	3.3	20
71	Predictors of acute care utilization and acute pain treatment outcomes in adults with sickle cell disease: The role of nonâ€hematologic characteristics and baseline chronic opioid dose. American Journal of Hematology, 2018, 93, 1127-1135.	4.1	18
72	Baby on board: what you need to know about pregnancy in the hemoglobinopathies. Hematology American Society of Hematology Education Program, 2012, 2012, 208-14.	2.5	18

#	Article	IF	Citations
73	Attitudes toward clinical trials among patients with sickle cell disease. Clinical Trials, 2014, 11, 275-283.	1.6	17
74	Diminished ovarian reserve in young women with sickle cell anemia. Blood, 2022, 139, 1111-1115.	1.4	17
75	The Association between Educational Attainment and Patterns of Emergency Department Utilization among Adults with Sickle Cell Disease. International Journal of Behavioral Medicine, 2016, 23, 300-309.	1.7	16
76	Treatment of Acute Pain in Adults With Sickle Cell Disease in an Infusion Center Versus the Emergency Department. Annals of Internal Medicine, 2021, 174, 1207-1213.	3.9	16
77	Graft failure in a patient with systemic lupus erythematosus (SLE) treated with high-dose immunosuppression and autologous stem cell rescue. Bone Marrow Transplantation, 2001, 27, 221-224.	2.4	15
78	2019 sickle cell disease guidelines by the American Society of Hematology: methodology, challenges, and innovations. Blood Advances, 2019, 3, 3945-3950.	5.2	14
79	Mortality and Access to Kidney Transplantation in Patients with Sickle Cell Diseaseâ€“Associated Kidney Failure. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 407-414.	4.5	14
80	The Association of Clinician Characteristics with their Attitudes Toward Patients with Sickle Cell Disease: Secondary Analyses of a Randomized Controlled Trial. Journal of the National Medical Association, 2015, 107, 89-96.	0.8	13
81	Patent Foramen Ovale in Patients with Sickle Cell Disease and Stroke: Case Presentations and Review of the Literature. Case Reports in Hematology, 2013, 2013, 1-5.	0.4	11
82	Overcoming challenges of venous thromboembolism in sickle cell disease treatment. Expert Review of Hematology, 2019, 12, 173-182.	2.2	11
83	The Economic Burden of End-Organ Damage Among Medicaid Patients with Sickle Cell Disease in the United States: A Population-Based Longitudinal Claims Study. Journal of Managed Care & Specialty Pharmacy, 2020, 26, 1121-1129.	0.9	11
84	Evaluation of a Train-the-Trainer Workshop on Sickle Cell Disease for ED Providers. Journal of Emergency Nursing, 2013, 39, 539-546.	1.0	10
85	Utility of the Montreal Cognitive Assessment as a Screening Test for Neurocognitive Dysfunction in Adults with Sickle Cell Disease. Southern Medical Journal, 2016, 109, 560-565.	0.7	10
86	The five key things you need to know to manage adult patients with sickle cell disease. Hematology American Society of Hematology Education Program, 2015, 2015, 420-425.	2.5	9
87	Quality Improvement Process in a Sickle Cell Infusion Center. American Journal of Medicine, 2015, 128, 541-544.	1.5	9
88	Efficacy and Safety of Ledipasvir/Sofosbuvir for the Treatment of Chronic Hepatitis C in Persons With Sickle Cell Disease. Clinical Infectious Diseases, 2017, 65, 864-866.	5.8	9
89	Women with sickle cell disease report low knowledge and use of long acting reversible contraception. Journal of the National Medical Association, 2021, 113, 552-559.	0.8	9
90	Metabolic syndrome among adults living with sickle cell disease. Blood Cells, Molecules, and Diseases, 2019, 74, 25-29.	1.4	8

#	Article	IF	Citations
91	Symptomatic Avascular Necrosis: An Understudied Risk Factor for Acute Care Utilization by Patients with SCD. Southern Medical Journal, 2016, 109, 519-524.	0.7	8
92	Acceptable, hopeful, and useful: development and mixed-method evaluation of an educational tool about reproductive options for people with sickle cell disease or trait. Journal of Assisted Reproduction and Genetics, 2022, 39, 183-193.	2.5	8
93	Self-perceived Loss of Control and Untreated Dental Decay in African American Adults With and Without Sickle Cell Disease. Journal of Health Care for the Poor and Underserved, 2006, 17, 641-651.	0.8	7
94	Challenges in the management of the transgender patient with sickle cell disease. American Journal of Hematology, 2018, 93, E360-E362.	4.1	7
95	Quality Metrics and Health Care Utilization for Adult Patients with Sickle Cell Disease. Journal of the National Medical Association, 2019, 111, 54-61.	0.8	7
96	GMI 1070: Reduction In Time To Resolution Of Vaso-Occlusive Crisis and Decreased Opioid Use In a Prospective, Randomized, Multi-Center Double Blind, Adaptive Phase 2 Study In Sickle Cell Disease. Blood, 2013, 122, 776-776.	1.4	7
97	The Montreal cognitive assessment as a cognitive screening tool in sickle cell disease: Associations with clinically significant cognitive domains. British Journal of Haematology, 2022, , .	2.5	7
98	The Role of Patient-Physician Communication on the Use of Hydroxyurea in Adult Patients with Sickle Cell Disease. Journal of Racial and Ethnic Health Disparities, 2019, 6, 1233-1243.	3.2	6
99	Sickle Cell Disease Mortality in the United States: Age at Death and Contributing Causes.. Blood, 2007, 110, 81-81.	1.4	6
100	Time to Recognize an Overlooked Trait. Journal of the American Society of Nephrology: JASN, 2010, 21, 385-386.	6.1	5
101	Effect of Free Dental Services on Individuals with Sickle Cell Disease. Southern Medical Journal, 2016, 109, 576-578.	0.7	5
102	Preliminary evidence that hydroxyurea is associated with attenuated peripheral sensitization in adults with sickle cell disease. Pain Reports, 2019, 4, e724.	2.7	5
103	Psychosocial and Clinical Risk Factors Associated with Substance Use in Observational Cohort of Patients with Sickle Cell Disease. Substance Use and Misuse, 2020, 55, 2205-2212.	1.4	5
104	Assessing the Safety and Efficacy of Converting Adults with Sickle Cell Disease from Full Agonist Opioids to Buprenorphine. Blood, 2018, 132, 856-856.	1.4	5
105	Screening for Neurocognitive Dysfunction in an Adult Population with Sickle Cell Disease. Blood, 2014, 124, 2717-2717.	1.4	5
106	Need for Specialized Centers to Provide Acute Care to Adults with Sickle Cell Disease. Southern Medical Journal, 2016, 109, 566-567.	0.7	5
107	Hospitalization Rates in Patients with Sickle Cell Disease (SCD) in the State of Maryland (MD): No Change Since Approval of Hydroxyurea (HU).. Blood, 2004, 104, 107-107.	1.4	5
108	Patent foramen ovale in adults with sickle cell disease and stroke. American Journal of Hematology, 2016, 91, E358-60.	4.1	4

#	Article	IF	Citations
109	Innovations in Targeted Antiâ€Adhesion Treatment for Sickle Cell Disease. Clinical Pharmacology and Therapeutics, 2020, 107, 140-146.	4.7	4
110	Kneeling Was the First Step for Sickle Cell Disease. Annals of Internal Medicine, 2021, 174, 1004-1005.	3.9	4
111	Gaps in the diagnosis and management of iron overload in sickle cell disease: a â€˜realâ€worldâ€™ report from the GRNDaD registry. British Journal of Haematology, 2021, 195, e157-e160.	2.5	4
112	GRNDaD: big data and sickle cell disease. Blood Advances, 2022, 6, 1088-1088.	5.2	4
113	Marijuana use and health behaviors in a US clinic sample of patients with sickle cell disease. PLoS ONE, 2020, 15, e0235192.	2.5	3
114	A community-centered approach to sickle cell disease and clinical trial participation: an evaluation of perceptions, facilitators, and barriers. Blood Advances, 2021, 5, 5323-5331.	5.2	3
115	Improving Inpatient Care for Individuals with Sickle Cell Disease Using the Project ECHO Model. Southern Medical Journal, 2016, 109, 568-569.	0.7	3
116	Pain without gain: steroids and sickle crisis. Blood, 2022, 139, 3678-3679.	1.4	3
117	Negative studies shape the state of sickle trait. Blood, 2017, 129, 661-662.	1.4	2
118	Look into my eyes: An unusual first presentation of sickle cell disease. American Journal of Hematology, 2017, 92, 968-971.	4.1	2
119	Societal Costs of Sickle Cell Disease in the United States. Blood, 2018, 132, 4706-4706.	1.4	2
120	Do Sickle Cell Patients Wait Longer to See Physicians in the Emergency Department?. Blood, 2011, 118, 2070-2070.	1.4	2
121	Effects Of GMI 1070, a Pan-Selectin Inhibitor, On Pain Intensity and Opioid Utilization In Sickle Cell Disease. Blood, 2013, 122, 775-775.	1.4	2
122	Successful Use of Pegylated Carboxyhemoglobin Bovine As an Emergency Treatment for Severe Anemia in a Patient with Sickle Cell Disease and Hyperhemolysis: A Case Report. Blood, 2014, 124, 4928-4928.	1.4	2
123	Modifiable Cardiovascular Risk Factors in Adults with Sickle Cell Disease. Blood, 2018, 132, 1088-1088.	1.4	2
124	Practice Guideline for Pulmonary Hypertension in Sickle Cell: Direct Evidence Needed before Universal Adoption. American Journal of Respiratory and Critical Care Medicine, 2014, 190, 237-238.	5.6	1
125	Low rates of transfusionâ€transmitted infection screening in chronically transfused adults with sickle cell disease. Transfusion, 2021, 61, 2421-2429.	1.6	1
126	Swaying sickle cell research forward in support of patient reported outcomes. American Journal of Hematology, 2021, 96, 402-403.	4.1	1

#	Article	IF	Citations
127	Predictors of In-Hospital Mortality and Charges in Sickle Cell Disease: Results from the California Discharge Databases 1998â€“2005.. Blood, 2007, 110, 432-432.	1.4	1
128	Trends In the Hospital Treatment of Sickle Cell Disease-Related Priapism In the United States: 1998 to 2007,. Blood, 2011, 118, 4195-4195.	1.4	1
129	Cost Benefit Analysis Of a Sickle Cell Infusion Center For The Treatment Of Vaso-Occlusive Crises. Blood, 2013, 122, 1697-1697.	1.4	1
130	Perceived Discrimination In Health Care Is Associated With Daily Chronic Pain In Sickle Cell Disease. Blood, 2013, 122, 5577-5577.	1.4	1
131	Metabolic Syndrome Risk Among Adults Living with Sickle Cell Disease. Blood, 2015, 126, 3405-3405.	1.4	1
132	Acute Care Utilization Is More Common in Patients with Sickle Cell Disease Who Have Chronic Complications and Chronic Pain: A Preliminary Report from the Escaped Trial. Blood, 2016, 128, 2490-2490.	1.4	1
133	Predictors of Six-Minute Walk Distance In Adults with Sickle Cell Anemia In the Walk-PHaSST Study. Blood, 2010, 116, 947-947.	1.4	1
134	Non-Cardiopulmonary Factors Affecting the Six-Minute Walk Distance in Patients with Sickle Cell Disease: Results From the Walk-PHaSST Study. Blood, 2011, 118, 1074-1074.	1.4	1
135	A Five Fold Decrease in Admissions for Uncomplicated Vaso-Occlusive Crisis and Other Benefits from Care in Infusion Clinics: Results from the Escaped Trial. Blood, 2018, 132, 853-853.	1.4	1
136	Liver Transplant in Hemoglobin SC Disease and Autoimmune Hepatitis: A Case Report. Experimental and Clinical Transplantation, 2022, , .	0.5	1
137	The Reply. American Journal of Medicine, 2013, 126, e15.	1.5	0
138	Pregnancy in Subjects with Hemoglobinopathies: Precautions and Management. , 2016, , 661-668.		0
139	Experience of Respect and Pain Management among Adult Patients with Sickle Cell Disease during Vaso-Occlusive Crisis.. Blood, 2006, 108, 3341-3341.	1.4	0
140	Risk Factors for Primary Hemorrhagic Stroke in Adults with Sickle Cell Disease.. Blood, 2007, 110, 3809-3809.	1.4	0
141	Documenting the Effectiveness of Hydroxyurea (HU) To Treat Sickle Cell Disease (SCD) in the Community Setting.. Blood, 2007, 110, 956-956.	1.4	0
142	NT-Probnp as a Marker of Cardiopulmonary Compromise and Exercise Limitation In Adults with Sickle Cell Anemia In the Walk-PHaSST Study. Blood, 2010, 116, 1639-1639.	1.4	0
143	Chronic Pain Is An Independent Predictor of Lower 6 Minute Walk Distance In Patients with Sickle Cell Disease: Results From Walk-PHaSST Study. Blood, 2010, 116, 2658-2658.	1.4	0
144	Trends In Mortality Rates and Age of Death In Sickle Cell Disease (SCD): 1979â€“2005. Blood, 2010, 116, 736-736.	1.4	0

#	Article	IF	Citations
145	Cigarette Smoking Is An Independent Predictor of Chronic Pain In Sickle Cell Patients: Results From the Walk-PHaSST Study. Blood, 2010, 116, 4804-4804.	1.4	0
146	Describing Adherence to Recommended Preventative Care Behaviors Among Adults with Sickle Cell Disease. Blood, 2012, 120, 2058-2058.	1.4	0
147	Polycythemia Vera: Redefinition in the Genomic Era. Blood, 2012, 120, 1754-1754.	1.4	0
148	Higher Baseline Hemoglobin and Splenectomy Are Risk Factors for Venous Thromboembolism in Adults with Sickle Cell Variant Genotypes. Blood, 2012, 120, 3243-3243.	1.4	0
149	Venous Thromboembolism Incidence In The Cooperative Study Of Sickle Cell Disease: The Untold Story. Blood, 2013, 122, 2214-2214.	1.4	0
150	Patent Foramen Ovale in Adult Patients with Sickle Cell Disease and Stroke. Blood, 2014, 124, 4084-4084.	1.4	0
151	Essential Thrombocytosis: Redefinition in the Genomic Era. Blood, 2014, 124, 3205-3205.	1.4	0
152	Avascular Necrosis: An Understudied Risk Factor for Acute Care Utilization By Patients with Sickle Cell Disease. Blood, 2014, 124, 2709-2709.	1.4	0
153	An Analysis of VTE Prophylaxis Practice in Oncology Patients after Implementation of a Standardized Mandatory Computerized Clinical Decision Support Tool. Blood, 2014, 124, 4859-4859.	1.4	0
154	Hospitalization for Acute Pain in Sickle Cell Disease: Changes in Clinical Parameters and Factors Predicting Hospital Discharge and Re-Admission. Blood, 2016, 128, 3662-3662.	1.4	0
155	Developmental Outcomes of Children Exposed to Maternal Sickle Cell Disease (SCD). Blood, 2017, 130, 983-983.	1.4	0
156	Iron Overload Is Under-Recognized and Under-Treated in SCD: A Report from the Grndad Registry. Blood, 2018, 132, 158-158.	1.4	0
157	Patient Satisfaction of Care in the Treatment of Vaso-Occlusive Crises: A Comparison of Emergency Department and Infusion Centers in the Escaped Study. Blood, 2018, 132, 314-314.	1.4	0
158	Health Care Utilization by Adolescent/Young Adult Patients With Sickle Cell Disease in Delaware. Cureus, 2022, 14, e22700.	0.5	0